Vladimir Jankovic

Learn More
Human placenta-derived adherent cells (PDAC cells) are a culture expanded, undifferentiated mesenchymal-like population derived from full-term placental tissue, with immunomodulatory and anti-inflammatory properties. PDA-001 (cenplacel-L), an intravenous formulation of PDAC cells, is in clinical development for the treatment of autoimmune and inflammatory(More)
Amino acids in rat systemic and portal vein plasma and jejunal and ileal gut contents after 7 days of feeding normoprotein (NP) and protein-free diet (PF) are investigated. Amino acid analyses revealed that ingestion of PF diet resulted in unusual amino acid patterns in both plasmas. Thus, while the levels and/or molar ratios of all indispensable amino(More)
BACKGROUND Decellularized, dehydrated human amniotic membrane (DDHAM) is an extracellular matrix devoid of cells, cell debris, and growth factors. This study examines the effect of cell attachment to the DDHAM and the induced cellular responses. MATERIALS AND METHODS The cell types employed in this study were human dermal fibroblasts (HDF), human(More)
Introduction Clinical studies have demonstrated that adoptive transfer of allogeneic Natural Killer (NK) cells can play a therapeutic role in hematological malignancies and potentially solid tumors. We established and characterized ex vivo methods to obtain murine NK1.1 cells from mouse fetal liver. These cells represent an orthologous cell type for(More)
Peripheral arterial disease (PAD) is a leading cause of limb loss and mortality worldwide with limited treatment options. Mesenchymal stromal cell (MSC) therapy has demonstrated positive effects on angiogenesis in preclinical models and promising therapeutic efficacy signals in early stage clinical studies; however, the mechanisms underlying MSC-mediated(More)
The objective of this study was to examine the safety of cenplacel (PDA-002) in patients with peripheral arterial disease (PAD) and a diabetic foot ulcer (DFU). Cenplacel is a mesenchymal-like cell population derived from full-term human placenta. This phase 1, dose-escalation study investigated cenplacel in diabetic patients with chronic DFUs (Wagner grade(More)